https://doi.org/10.4081/hmr.v2i5.380

An update of the apex study

Vol. 2 No. 5: Bortezomib (Velcade®) in multiple myeloma: an update
Published: June 8, 2009
Abstract Views: 268
PDF: 1310
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Alessandro Corso
support@pagepress.org
APEX, a pivotal phase III, randomized, multicentre trial was the largest performed in relapsed multiple myeloma (MM) to date, comparing Bortezomib (Velcade®) with high dose dexamethasone (Dex). The initial results of this important study were published by Paul Richardson and colleagues in the New England Journal of Medicine (NEJM) in 2005. Since these results were published, all Velcade patients who were ongoing at the time of the NEJM publication have completed study participation (i.e. completed all cycles or discontinued the study). However, because of dexamethasone arm was halted early, the results, apart from overall survival, have only been updated for Bortezomib (Velcade®) patients.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Corso, A. (2009). An update of the apex study. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.380
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).